Published on 28 October 2025
In a powerful show of unity against a common childhood illness, Sanofi has made history with its Together Against RSV campaign – setting a new Singapore Book of Records title for the “Largest Mural of Magnetic Hands”, a public pledge against RSV.
The vibrant installation featured over 1,000 magnetic hand pledges, each representing a parent, caregiver, or supporter committed to protecting infants from Respiratory Syncytial Virus (RSV) — a highly contagious respiratory infection that can cause severe illness in young children.
A National Pledge for Infant Health
Held over three days at Serangoon NEX, the event brought together families, healthcare professionals, and community members who placed colourful hand-shaped magnets on a massive mural. Each hand symbolised a personal promise to learn about RSV and take action to prevent it.
The mural, standing 2 meters tall and spanning 5.1 meters wide, now serves as a lasting reminder of the nation’s shared commitment to child health.
“This record is more than just numbers; it is a symbol of unity and a testament to the collective power of Singaporean families, healthcare professionals, and communities coming together for a cause that truly matters,” said Zainab Sadat, Vaccines General Manager, Sanofi SEA & India.
“Through our Together Against RSV campaign, we hope to spark ongoing conversations about RSV and empower parents with knowledge and preventive measures, including immunisation options, to protect their little ones. Together, we are building a future where every baby can breathe a little easier, and every family can rest a little more peacefully.”
Raising Awareness Through Partnership and Education
The Together Against RSV initiative is part of Sanofi’s wider mission to raise public awareness about RSV. The campaign includes partnerships with hospitals, parenting communities, and educational platforms such as the TogetherAgainstRSV.sg microsite, created in collaboration with the Singapore Paediatric Society.
These efforts aim to help parents better understand RSV and explore ways to prevent infection, including the role of vaccination and good hygiene practices.
Understanding RSV and Its Impact
Respiratory Syncytial Virus (RSV) is a common but potentially serious virus that affects the respiratory system and is one of the leading causes of hospitalisation among infants worldwide, including otherwise healthy, full-term babies.²˒³
Globally, two out of three infants contract RSV before their first birthday, and almost all children are infected by age two.¹ In 2019, there were approximately 33 million cases of RSV-related lower respiratory infections leading to over three million hospitalisations and an estimated 26,300 in-hospital deaths among children under five years old.⁸
In Singapore, RSV is also a major cause of infant hospitalisation. Each year, an estimated 1,804 children under 29 months are hospitalised due to RSV-related illnesses.⁷
A Step Toward a Healthier Future
Through initiatives like Together Against RSV, Sanofi hopes to foster stronger community awareness, encourage early prevention, and support caregivers in keeping their children healthy.
By turning thousands of pledges into a record-breaking mural, Sanofi has not only earned a place in the Singapore Book of Records but also strengthened a nationwide movement dedicated to protecting the youngest members of society.
For more information about RSV, visit TogetherAgainstRSV.sg or speak to your healthcare professional about preventive measures, including immunisation recommendations.
MAT-SG-2500364-1.0-10/2025
- Walsh, EE. Respiratory Syncytial Virus Infection: An Illness for All Ages. Clinics in Chest Medicine. 2017;38(1):29-36.
- Karron A. Respiratory Syncytial Virus Vaccines and Monoclonal antibodies. Orenstein W, Offit P, Edwards KM, Plotkin S. Plotkin’s Vaccines, eighth edition: 998-1004. Elsevier 2023.
- Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003;143(5 Suppl):S127-S132. doi:10.1067/s00223476(03)00510-9.
- Zhou H, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis. 2012;54:1427–1436.
- Rha B, et al. Respiratory Syncytial Virus-Associated Hospitalizations Among Young Children: 2015-2016. Pediatrics. 2020;146:e20193611.
- Arriola CS, et al. Estimated Burden of Community-Onset Respiratory Syncytial Virus-Associated Hospitalizations Among Children Aged <2 Years in the United States, 2014-15. J Pediatric Infect Dis Soc. 2020;9:587-595
- Tam CC, et al. Burden and Cost of Hospitalization for Respiratory Syncytial Virus in Young Children, Singapore. Emerg Infect Dis. 2020 Jul;26(7):1489-1496
- Li Y, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 2022;399:92047–64.
- Zhang S, et al. Cost of Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection Management in Young Children at the Regional and Global Level: A Systematic Review and Meta-Analysis. J Infect Dis. 2020;222(Suppl 7):S680-687.
